The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
 
Michelino De Laurentiis
Honoraria - Amgen; AstraZeneca; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Genzyme; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Takeda
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genzyme (Inst); Lilly; Macrogenics (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
 
Luis Costa
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Novartis; SERVIER
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche
 
Joseph Gligorov
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Immunomedics; Ipsen; MacroGenics; MSD; Novartis; Onxeo; Pfizer; Roche/Genentech; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Immunomedics; Ipsen; MacroGenics; MSD; Novartis; Onxeo; Pfizer; Roche/Genentech; Seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Immunomedics; Ipsen; MacroGenics; MSD; Novartis; Onxeo; Pfizer; Roche/Genentech; Seagen
Research Funding - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; MSD; Novartis; Pfizer; Roche/Genentech
Expert Testimony - AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Immunomedics; Ipsen; MacroGenics; MSD; Novartis; Onxeo; Pfizer; Roche/Genentech; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Genomic Health; MSD; Novartis; Pfizer; Roche; Seagen
 
Ann Knop
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences; Lilly; Merck; Novartis; Pfizer; Roche
Research Funding - Daiichi Sankyo; Sanofi
 
Elzbieta Senkus-Konefka
Stock and Other Ownership Interests - AstraZeneca; Lilly; Pfizer
Honoraria - Cancerodigest; Curio Science; Egis Pharmaceuticals; Genomic Health; Gilead Sciences; High5md; Lilly; Novartis; Oncompass; Pfizer
Consulting or Advisory Role - AstraZeneca; Egis Pharmaceuticals; Genomic Health; Gilead Sciences; Novartis; Oncompass; Pfizer
Research Funding - Amgen; AstraZeneca; Lilly; Novartis; Pfizer; Roche; Samsung
Travel, Accommodations, Expenses - Egis Pharmaceuticals; Novartis; Pfizer; Roche
 
José A. García-Sáenz
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Seagen
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Novartis; Roche
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Aurelia Heniquez
Employment - AstraZeneca (I); Novartis
Leadership - AstraZeneca (I)
Stock and Other Ownership Interests - AstraZeneca (I); Novartis
 
Paolo Serra
Employment - Novartis
Stock and Other Ownership Interests - Alcon; Novartis
 
Albert Reising
Employment - Novartis; Novartis
Stock and Other Ownership Interests - Novartis
 
Sherko Kuemmel
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; Seagen; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape
(OPTIONAL) Uncompensated Relationships - West German Study Group